Agilus Diagnostics, a global leader specializing in pathology and radiology diagnostics, has introduced the revolutionary Claudin 18.2 test, setting a new benchmark in cancer diagnostics.
This innovative step underscores Agilus Diagnostics’ ongoing dedication to pioneering diagnostic advancements.
Gastric cancer ranks as the fifth and seventh most prevalent cancer among men and women, respectively, in India. Due to the aggressive nature of the disease and the pressing demand for better treatment options, breakthroughs like the Claudin 18.2 test are pivotal for enhancing cancer care outcomes. Astonishingly, gastric cancer represents the second leading cause of cancer mortality among Indian men and women aged 15 to 44.
The Claudin 18.2 test, a cutting-edge diagnostic approach, accurately detects the Claudin 18.2 protein—a key biomarker for gastric, pancreatic, and other forms of cancer. By identifying this biomarker, the test provides oncologists with essential information, helping them to determine patients suitable for targeted therapies, thus boosting treatment efficacy and advancing the field of personalized medicine.
Dr. Anand K, the Managing Director and CEO of Agilus Diagnostics, remarked, “Claudin 18.2 is crucial in cancer care, particularly for patients with gastric cancer. The test’s ability to enhance diagnostic accuracy is a crucial step towards personalized medicine. It enables healthcare providers to customize treatments, thus greatly enhancing patient outcomes. We at Agilus Diagnostics are delighted to introduce this advanced diagnostic solution to India, backing both oncologists and patients in their fight against cancer. Our mission is to push the boundaries of diagnostic science and healthcare by adopting future-forward therapies and personalized medicine, maintaining our alignment with this transformative vision.”
Dr. Kunal Sharma, Associate Director and Head of the Histopathology Center of Excellence at Agilus Diagnostics, added, “In October 2024, the FDA approved zolbetuximab-clzb, an antibody therapy targeting Claudin 18.2, to be used alongside chemotherapy for initial treatment in adults with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancers that show CLDN18.2 positivity. The FDA also sanctioned the VENTANA CLDN18 assay as a companion diagnostic test to identify suitable patients for this therapy. Agilus Diagnostics’ introduction of the FDA-approved Claudin 18.2 test in India aligns with these global therapeutic advancements, bringing cutting-edge solutions to the forefront of Indian oncology.”
He emphasized that Agilus Diagnostics is committed to staying at the forefront of laboratory medicine by integrating state-of-the-art technology and research capabilities. With robust infrastructure, including AI-driven digital pathology and a focus on innovation, they continue to deliver exceptional diagnostic services.
Agilus Diagnostics Ltd boasts an extensive network of over 410 laboratories, upwards of 3,900 customer touchpoints, and more than 14,000 direct clients across over 1,000 cities in 34 states and union territories. Offering a comprehensive range of more than 3,800 tests and test combinations, from routine tests to advanced molecular and genetic assays, the company holds the distinction of having the most accredited labs in the country with over 40 NABL-accredited and 2 CAP-accredited laboratories. Their international network spans over 1,000 customer interaction points, including over 120 collection centers and 800 direct clients, throughout regions such as SAARC, Sub-Saharan Africa, Southeast Asia, CIS, the Gulf, and the Middle East.